A PROSPECTIVE, RANDOMIZED STUDY USING ULINASTATIN FOR THE TREATMENT OF PATIENTS WITH SEVERE SEPSIS
Farhana Bashir¹, Mushtaq Ahmad Rather², Basharat Saleem³, Abdul Hamid⁴

HOW TO CITE THIS ARTICLE:
Farhana Bashir, Mushtaq Ahmad Rather, Basharat Saleem, Abdul Hamid. “A Prospective, Randomized Study using Ulinastatin for the Treatment of Patients with Severe Sepsis”. Journal of Evolution of Medical and Dental Sciences 2014; Vol. 3, Issue 53, October 16; Page: 12241-12246, DOI: 10.14260/jemds/2014/3618

ABSTRACT: A prospective, randomized study was conducted on patients of severe sepsis using ulinastatin for treatment. Total of 50 patients were taken up for this study who were randomly assigned in two groups: 25 patients in group A who were given ulinastatin and 25 patients in group B who were given placebo. Patients were evaluated clinically using Acute physiology and chronic health evaluation (APACHE), Multiple organ failure (MOF) and Glasgow coma score (GCS), at the time of admission and after therapy on the 3rd, 8th and 28th day. RESULTS: There was a significant difference between the two groups regarding the organ failure scores. Patients in group A showed a better performance in APACHE II, MOF and GCS as compared to patients in group B on 3rd, 8th and 28th day of admission. CONCLUSION: Ulinastatin has a beneficial role in the treatment of patients with severe sepsis. KEYWORDS: Ulinastatin, Severe sepsis, Organ failure scores.

INTRODUCTION: Sepsis is defined as the presence (probable or documented) of infection together with systemic manifestations of infection [sepsis guidelines 2012]. Severe sepsis is defined as sepsis plus sepsis induced organ dysfunction or tissue hypoperfusion.[8] Sepsis has been reported to be the most common cause of death in non-coronary ICUs. Even with optimal treatment, mortality due to severe sepsis or septic shock is approximately 40% and can exceed 50% in the sickest patients.[3,10,15,21]

During sepsis bacterium leads to a decrease in both number and function of circulating lymphocytes through the mechanism of cell apoptosis with resultant immunosuppression. Initially there is an increase in the concentration of cytokines like IL-1β, IL-6 and TNF-α.[5] Increased expression of CD64 on polymorphonuclear leukocytes indicates cellular activation[evaluation of sepsis]. Therapies like high dose steroids and TNFα antibodies have been tried but proved to be ineffective.

Ulinasttin, a protease inhibitor (kunitz-type) has an anti-inflammatory and anticoagulant action. It is extracted from human urine. It inhibits inflammatory markers: trypsin, pancreatic elastase and the endotoxin stimulated production of TNFα and interleukin 1, 8 and 6. It inhibits coagulation and fibrinolysis and promotes microperfusion. Thus, ulinasttin is an effective agent for immune modulation to prevent organ dysfunction and promote homeostasis.

Present study was conducted to see the effect of ulinasttin for treating severe sepsis.

MATERIAL AND METHODS: The study was conducted in the department of Anaesthesiology and Critical care GMC Srinagar from July 2013 to July 2014. Fifty patients with the diagnosis of severe sepsis were taken up for the study. Exclusion criteria were:

- Age<18years or>80years.
• Chronic compensated organ dysfunction.
• Incurable malignancies.
• Patients on treatment with immunosuppressive drugs.

The patients were randomly assigned to two groups of 25 patients each, clinically evaluated and investigated. After obtaining informed consent, patients in group A received 2 lakh IU of ulinastatin two times a day and an equal amount of normal saline (NS) was given to patients in placebo group for a period of 7 days. Patients in both the groups received treatment as per the ICU protocol regarding IV fluids, antimicrobial therapy, cardiovascular\ respiratory support and surgical intervention.

Monitoring of vital signs like heart rate, blood pressure, oxygen saturation, temperature and end tidal CO2 was done continuously. GCS of the patients was assessed from time to time. Besides, biochemical and hematological tests were done at the time of admission and on 3rd, 8th and 28th day. These laboratory values and organ specific parameters were used to calculate APACHE II and MOF.

Statistical Analysis: The data collected was tabulated and analyzed by Graph Pad instat 3. Data was expressed as means and standard deviation (SD), medians and ranges or number and percentages. For statistical comparison student’s paired and un-paired t-test was applied. P value < 0.05 was considered as significant.

RESULTS:
Patient characteristics on Admission: On admission, mean age, sex (M/F), body weight (kg), mean APACHE II score, MOF scores and Glasgow score were recorded. This distribution, as well as the demographic characteristics, the severity of sepsis at study entry were well-balanced across the two treatment groups (P >0.05). Treatment with UTI was found to be well-tolerated and safe without adverse events (Table 1 & 2).

| Demographic characteristics | Group A (n=25) | Group B (n=25) | P-Value |
|-----------------------------|---------------|---------------|---------|
| Age (Years, mean±SD)       | 50±4.25       | 52±6.49       | 0.3647  |
| Gender (M/F)               | 15/10         | 16/9          |         |
| Weight (Kg, mean±SD)       | 72±6.97       | 74±7.34       | 0.2166  |

Table 1: General characteristics of the two groups

| Parameters     | Group A       | Group B       |
|----------------|---------------|---------------|
| APACHE II (mean±SD) | 15.2±3.39   | 15.28±3.28    |
| MOF (mean±SD)     | 12.4±3.27    | 12.72±4.46    |
| GCS (mean±SD)     | 8.64±2.54    | 8.24±1.71     |

Table 2: APACHE II, MOF and GCS (Glasgow) scores on admission

Effects of UTI in patients with severe Sepsis: APACHE II and MOF were reduced significantly after therapy on the 3rd, 8th and 28th day in Group A (P=0.0091, 0.0001, 0.0001 and 0.010, 0.0001, 0.0001 respectively), so did in Group B only after therapy on 28th day when compared with that on admission (P=0.029, 0.017, respectively). (Tables 3, 4)
**DISCUSSION:** Sepsis is a clinical syndrome characterized by systemic inflammation due to infection. There is a continuum of severity ranging from sepsis to severe sepsis and septic shock. Besides the conventional treatment, new therapies for sepsis have been tried from time to time including monoclonal antibodies, NSAIDS and high dose steroids, but have failed to show good results.\[5\]

It has been shown that levels of proteases such as elastase are typically increased in cases of inflammation and/or infection and any substance that can inhibit this protease results in an anti-inflammatory effect.\[10\] α1-protease inhibitor (α1-PI) and ulinastatin are intrinsic physiologic protease inhibitors which suppress PMNE activity. In inflammatory tissues, α1-PI loses its ability to function in acidic conditions, but ulinastatin can continue to inhibit PMNE.\[14\]
Our study attempted to address the beneficial role of ulinastatin in organ failure scores in patients of severe sepsis. We compared difference in APACHE II, MOF and GCS among the two groups on 3rd, 8th and 28th day of admission.

There was a significant improvement in organ failure scores in group A as compared to group B. GCS improved on 8th day of admission in group A, whereas it improved on 28th day of admission in group B.

Ulinastatin, clinically used for the treatment of circulatory shock, hemorrhagic shock in trauma patients,[7] septic shock, burn sepsis,[19] acute pancreatitis,[9] ARDS[1,14,19] has a variety of therapeutic mechanisms:

1. Suppression of protease secretion from neutrophils via stabilization of lysosomal membranes.
2. Activity inhibition of neutrophil elastase and other proteases.
3. An inhibitory effect on the production of cytokines and adhesion molecules.
4. Anti-inflammatory effect and
5. Antioxidation.[2,4,6,12,13,20]

REFERENCES:

1. Akashi K, Ishimaru T, Shibuya T, Harada M, Niho Y. Human urinary proteinase inhibitor in the treatment of P. carinii pneumonia. Chest. 1991; 99:1055–1056.
2. Aosasa S, Ono S, Mochizuki H, Tsujimoto H, Ueno C, Matsumoto A. Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes. Shock. 2001; 15:101–105.
3. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997; 336:912.
4. Bingyang J, Jinping L, Mingzheng L, Guyan W, Zhengyi F. Effects of urinary protease inhibitor on inflammatory response during on-pumP coronary revascularization: effect ulinastatin on inflammatory response. J Cardiovasc Surg. 2007; 48: 497–503.
5. CHEN Hao, HE Ming-yan and LI Yu-min. Treatment of patients with severe sepsis using Ulinastatin and Thymosin α1: a prospective, randomized, controlled pilot study. Chinese Medical Journal 2009; 122 (8): 883-888.
6. Gao C, Huan J, Li W, Tang J. Protective effects of ulinastatin on pancreatic and renal damage in rats following early scald injury. Burns. 2009; 35: 547–552.
7. kyung Hye Park, Kang Hyun Lee, Hyun Kim, Sung Oh Hwang. The anti-inflammatory effects of ulinastatin in trauma patients with hemorrhagic shock. Journal of Korean medical sciences. 2010 Jan; 25 (1): 128-134.
8. Levy MM, Fink MP, Marshall JC et al\ (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 31:1250–1256.
9. LIN Sen, LUO Xiang-Xiang, LIU Song-Ping Department of Surgery, Hainan Provincial 3rd People’s Hospital, Sanya 572000, China; Ulinastin in treatment of acute pancreatitis[J]; Journal of the Fourth Military Medical University; 2008-16.
10. Mania-Pramanik J, Potdar SS, Vadigoppula A, Sawant S. Elastase: a predictive marker of inflammation and/or infection. J Clin Lab Anal., 2004; 18: 153–158.
11. McCloskey RV, Straube RC, Sanders C, et al. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 1994; 121:1.

12. Nakatani K, Takeshita S, Tsujimoto H, Kawamura Y, Sekine I. Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J Leukocyte Biol. 2001; 69: 241–247.

13. Nishijima J, Hiraoka N, Murata A, Oka Y, Kitagawa K, Tanaka N, Toda H, Mori T. Protease inhibitors (gebexate mesylate and ulinastatin) stimulate intracellular chemiluminescence in human neutrophils. J Leukocyte Biol. 1992; 52:262–268.

14. Ogawa M, Nishibe S, Mori T, Neumann S. Effect of human urinary trypsin inhibitor on granulocyte elastase activity. Res Commun Chem Pathol Pharmacol 1987; 55:271–274.

15. Sasse KC, Nauenberg E, Long A, et al. Long-term survival after intensive care unit admission with sepsis. Crit Care Med 1995; 23:1040.

16. Sato N, Murakami K, Ishida K, Ikeda K, Saito K. Pulmonary hypertension and polymorphonuclear leukocyte elastase after esophageal cancer operations. Ann Thorac Surg. 1991; 51:754 –758.

17. Takashi Kanai, Takahiro Ishiwata, Tohru Kobayashi, Hiroki Sato, Mari Takizawa, Yoichi Kawamura, Hiroshi Tsujimoto, Keigo Nakatani, Naoko Ishibashi, Mitsunori Nishiyama, Yoshiho Hatai, Yuh Asano, Tomio Kobayashi, Seiichiro Takeshita and Shigeaki Nonoyama. Circulation. 2011; 124:2822-2828.

18. Tani T, Abe H, Endo Y, Hanasawa K, Kodama M. Effects of a urinary trypsin inhibitor on acute circulatory insufficiency after surgical operation. Am J Surg. 1998; 175:142–145.

19. Wang Chun-hua, HU De-lin, YU You-xin, FANG Lin-sen, XU Qing-lian, Wang Chang-rong. Clinical effects of ulinastatin in patients with severe burn sepsis. Anhui medical and pharmaceutical journal 2010-2011.

20. Zaitsu M, Hamasaki Y, Tashiro K, Matsuo M, Ichimaru T, Fujita I, Tasaki H, Miyazaki S. Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease. J Infect Dis. 2000; 181:1101–1109.

21. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997; 25:1095. Mania-Pramanik J, Potdar SS, Vadigoppulla A, Sawant S. Elastase: a predictive marker of inflammation and/or infection. J Clin Lab Anal 2004; 18: 153–158.
AUTHORS:
1. Farhana Bashir
2. Mushtaq Ahmad Rather
3. Basharat Saleem
4. Abdul Hamid

PARTICULARDS OF CONTRIBUTORS:
1. Resident Specialist, Department of Anaesthesia and Intensive Care, Government Medial College, Srinagar.
2. Senior Resident, Department of Anaesthesia and Intensive Care, Government Medial College, Srinagar.
3. Professor and HOD, Department of Anaesthesia and Intensive Care, Government Medial College, Srinagar.

4. Professor, Department of Anaesthesia and Intensive Care, Government Medial College, Srinagar.

NAME ADDRESS EMAIL ID OF THE CORRESPONDING AUTHOR:
Mushtaq Ahmad Rather,
Department of Anaesthesiology and Critical Care,
Government Medical College,
Srinagar-190001,
Jammu and Kashmir.
Email: mushtaqahmad767@gmail.com

Date of Submission: 22/08/2014.
Date of Peer Review: 23/08/2014.
Date of Acceptance: 09/10/2014.
Date of Publishing: 14/10/2014.